trending Market Intelligence /marketintelligence/en/news-insights/trending/p_cAanHs8zJNHg0b7B0rEA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

ImmunoGen plans common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ImmunoGen plans common stock offering

ImmunoGen Inc. plans to offer and sell 13 million common shares in an underwritten public offering.

The company plans to grant underwriters an option to buy up to an additional 15% of the shares offered.

Net proceeds will be used to fund the company's operations, including research and development activities, clinical trial activities, manufacturing and supply of drug substance and drug products, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the proposed offering. Canaccord Genuity is acting as co-manager for the proposed offering.